2,4-Difluoro-1-(2-methylbutyl)benzene

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,4-Difluoro-1-(2-methylbutyl)benzene
• 英文别名: 2,4-difluoro-1-(2-methylbutyl)benzene
• 化学式: C₁₁H₁₄F₂
• 分子量: 184.23
• InChiKey: CAYJPEYTHZDOIR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Potent non-urea inhibitors of soluble epoxide hydrolase
  申请人：THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

  公开号：US10005732B2

  公开（公告）日：2018-06-26

  The present invention relates to compounds that exhibit vasodilatory and anti-inflammatory effects by inhibiting the activity of soluble epoxide hydrolase (sEH). The present invention is also directed to methods of identifying such compounds, and use of such compounds for the treatment of diseases related to dysfunction of vasodilation, inflammation, and/or endothelial cells. In particular non-limiting embodiments, components of the invention may be used to treat hypertension.

  本发明涉及通过抑制可溶性环氧化物水解酶（sEH）的活性而表现出扩张血管和抗炎作用的化合物。本发明还涉及鉴定此类化合物的方法，以及使用此类化合物治疗与血管扩张、炎症和/或内皮细胞功能障碍有关的疾病。在特别的非限制性实施方案中，本发明的成分可用于治疗高血压。
• Malic enzyme inhibitors
  申请人：SUN PHARMA ADVANCED RESEARCH COMPANY LTD

  公开号：US11225480B2

  公开（公告）日：2022-01-18

  The present invention relates to novel compounds useful as malic enzyme (ME) inhibitors, processes for their preparation and use of these compounds for the therapeutic treatment of disorders mediated by ME such as cancers (e.g. pancreatic ductal adenocarcinoma (PDAC)) in humans. The novel compounds have a structure according to Formula I or a pharmaceutically acceptable salt, stereoisomer or deuterated analog thereof, wherein X, R1, R2 and Y are as described herein.

  本发明涉及可用作苹果酸酶（ME）抑制剂的新型化合物、其制备工艺以及这些化合物用于治疗由ME介导的疾病，如人类癌症（如胰腺导管腺癌（PDAC））。这些新型化合物具有符合式 I 的结构 或其药学上可接受的盐、立体异构体或氚代类似物，其中 X、R1、R2 和 Y 如本文所述。
• Lysyl oxidase-like 2 inhibitors and uses thereof
  申请人：PharmAkea, Inc.

  公开号：US11358936B2

  公开（公告）日：2022-06-14

  Described herein are compounds that are LOXL2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.

  本文描述了作为 LOXL2 抑制剂的化合物、制造此类化合物的方法、包含此类化合物的药物组合物和药物，以及使用此类化合物治疗与 LOXL2 活性相关的病症、疾病或失调的方法。
• DIAMIDE INHIBITORS OF CYTOCHROME P450
  申请人：Sequoia Pharmaceuticals, Inc.

  公开号：EP2257160B1

  公开（公告）日：2017-07-05
• METHODS FOR INHIBITING TUMORS AND DRUG RESISTANCE
  申请人：SEQUOIA PHARMACEUTICALS, INC.

  公开号：US20170354636A1

  公开（公告）日：2017-12-14

  Compositions and methods are provided for improving the treatment of tumors by inhibiting cytochrome P450 enzymes (“CYPs”) expressed by tumors. Inhibition of tumor-expressed CYPs provides improved dosing of anti-tumor drugs, inhibits development of drug resistance by tumors and provides improved patient outcomes.